| ORIGINAL ARTICLE |
|
| Year : 2018 | Volume
: 10
| Issue : 4 | Page : 162-168 |
|
|
A retrospective analysis of efficacy and safety of intralesional triamcinolone injections in the treatment of frontal fibrosing alopecia either as monotherapy or as a concomitant therapy
Maria-Angeliki Gkini, Rashid Riaz, Victoria Jolliffe
Department of Dermatology, The Royal London Hospital, Barts Health NHS Trust, London, UK
Correspondence Address:
Dr. Maria-Angeliki Gkini
Royal London Hospital, Whitechapel Rd, E1 1BB, London
UK
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijt.ijt_46_18
|
|
|
Context: Frontal fibrosing alopecia (FFA) is a primary cicatricial alopecia characterized by progressive recession of frontal, and often temporoparietal, hairline mainly in postmenopausal women. Currently, there are no guidelines or proposed evidence-based treatment for FFA. Aims: The aim of this study was to retrospectively evaluate the effect and safety of intralesional triamcinolone acetonide injections (ITAIs) either as monotherapy or as concomitant treatment in the management of hairline recession in FFA. Subjects and Methods: All patients with FFA, who visited our specialist hair clinic from July 2012 to October 2016 and were treated with ITAI either as monotherapy or as concomitant treatment, were enrolled in our study. Measurements were performed from five different points on the scalp. The analysis of data included demographics, associated symptoms, clinical and dermoscopic findings, comorbidities, family history of FFA, concomitant medication, treatment outcome, and recording of adverse events. Statistical Analysis: Statistical analysis was performed using the Statistical Package for the Social Sciences, version 22.0. Results: A total of 40 patients, all females were enrolled in our study. The mean age of the patients was 65.88 ± 8.18 whereas the mean age of the diagnosis was 61.24 ± 7.4. A total of 39 patients were treated with a combination of treatments, including ITAI, and only one with ITAI as monotherapy. There was a halting of the progress of the disease, and no significant adverse events were noted, apart from mild pain. Conclusions: A halting in the progression of FFA was achieved, with unremarkable adverse events. ITAI could serve as an effective and safe option for the treatment of FFA, although difficult to assess it as monotherapy. Further randomized controlled trials are needed to evaluate its efficacy and safety as the sole treatment in the management of FFA.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
